GlassScriptPhysician profile
Ankur Aggarwal
NPI 1275820870
$13,608.42
in general payments reported to CMS, 2019-2025
24 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,286 · 2020: $1,332 · 2021: $917 · 2022: $3,477 · 2023: $1,747 · 2024: $1,440 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Travel and Lodging: $1,010 · Consulting Fee: $146 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.35 |
| Travel and Lodging | $1,009.71 |
| Consulting Fee | $146.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,761.35 | 2021-2024 | Venaseal, Pivox Oblique Lateral Spinal System, Cd Horizon Spinal System |
| W. L. Gore & Associates, INC. | $2,399.48 | 2019-2022 | |
| Medtronic Vascular, INC. | $2,147.91 | 2019-2020 | |
| Abbott Laboratories | $1,084.54 | 2019-2022 | |
| Silk Road Medical, INC. | $733.44 | 2021 | |
| Stryker Corporation | $377.03 | 2023-2025 | Cascadia Interbody System |
| Angiodynamics, INC. | $307.34 | 2021-2023 | Auryon Laser System 100-120 Vac |
| Philips North America LLC | $211.98 | 2020-2023 | |
| Bard Peripheral Vascular, INC. | $177.90 | 2022-2023 | Lutonix Drug Coated Balloon |
| Zynex Medical, INC. | $173.01 | 2025 | Nexwave |
| Cardiovascular Systems INC. | $172.59 | 2022 | |
| Penumbra, INC. | $160.15 | 2023 | Indigo System |
| Lemaitre Vascular, INC. | $150.42 | 2022-2023 | Restoreflow, Tyke, Patch, Pledget and Intracardiac |
| Terumo Medical Corporation | $134.03 | 2022-2024 | Azur Cx Detachable |
| Janssen Pharmaceuticals, INC | $132.97 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $131.55 | 2022-2023 | Varithena Administration Pack |
| Janssen Scientific Affairs, LLC | $124.63 | 2022 | |
| Endologix LLC | $92.66 | 2022 | |
| Becton, Dickinson and Company | $29.00 | 2025 | Power-Trialysis |
| Tactile Systems Technology INC | $26.47 | 2024 | Entre Plus, Flexitouch Plus |
| Inari Medical, INC. | $25.02 | 2022 | |
| Depuy Synthes Sales INC. | $24.26 | 2025 | Milagro, Truespan Orthocord, Dynatape |
| Amgen INC. | $16.94 | 2022 | |
| Cashflow Solutions, LLC | $13.75 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.